245 related articles for article (PubMed ID: 30663095)
1. Preparation of
Pandey U; Kameswaran M; Gamre N; Dash A
J Labelled Comp Radiopharm; 2019 Apr; 62(4):158-165. PubMed ID: 30663095
[TBL] [Abstract][Full Text] [Related]
2. A comparative evaluation of the chelators H4octapa and CHX-A″-DTPA with the therapeutic radiometal (90)Y.
Price EW; Edwards KJ; Carnazza KE; Carlin SD; Zeglis BM; Adam MJ; Orvig C; Lewis JS
Nucl Med Biol; 2016 Sep; 43(9):566-576. PubMed ID: 27419360
[TBL] [Abstract][Full Text] [Related]
3. AAZTA
Klasen B; Moon ES; Rösch F
Nucl Med Biol; 2021; 96-97():80-93. PubMed ID: 33839678
[TBL] [Abstract][Full Text] [Related]
4. A systematic study on the utility of CHX-A''-DTPA-NCS and NOTA-NCS as bifunctional chelators for
Pandey U; Gamre N; Lohar SP; Dash A
Appl Radiat Isot; 2017 Sep; 127():1-6. PubMed ID: 28478331
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of (177)Lu-CHX-A''-DTPA-Bevacizumab as a radioimmunotherapy agent targeting VEGF expressing cancers.
Kameswaran M; Pandey U; Gamre N; Vimalnath KV; Sarma HD; Dash A
Appl Radiat Isot; 2016 Aug; 114():196-201. PubMed ID: 27258216
[TBL] [Abstract][Full Text] [Related]
6. Enhanced efficacy of radioimmunotherapy with 90Y-CHX-A''-DTPA-hu3S193 by inhibition of epidermal growth factor receptor (EGFR) signaling with EGFR tyrosine kinase inhibitor AG1478.
Lee FT; Mountain AJ; Kelly MP; Hall C; Rigopoulos A; Johns TG; Smyth FE; Brechbiel MW; Nice EC; Burgess AW; Scott AM
Clin Cancer Res; 2005 Oct; 11(19 Pt 2):7080s-7086s. PubMed ID: 16203806
[TBL] [Abstract][Full Text] [Related]
7. Preclinical evaluation of (177)lu-nimotuzumab: a potential tool for radioimmunotherapy of epidermal growth factor receptor-overexpressing tumors.
Vera DR; Eigner S; Beran M; Henke KE; Laznickova A; Laznicek M; Melichar F; Chinol M
Cancer Biother Radiopharm; 2011 Jun; 26(3):287-97. PubMed ID: 21711096
[TBL] [Abstract][Full Text] [Related]
8. PET imaging of HER1-expressing xenografts in mice with 86Y-CHX-A''-DTPA-cetuximab.
Nayak TK; Regino CA; Wong KJ; Milenic DE; Garmestani K; Baidoo KE; Szajek LP; Brechbiel MW
Eur J Nucl Med Mol Imaging; 2010 Jul; 37(7):1368-76. PubMed ID: 20155263
[TBL] [Abstract][Full Text] [Related]
9. Preparation of
Kameswaran M; Pandey U; Gamre N; Sarma HD; Dash A
Appl Radiat Isot; 2019 Jun; 148():184-190. PubMed ID: 30974402
[TBL] [Abstract][Full Text] [Related]
10. Anti-EGFRvIII monoclonal antibody armed with 177Lu: in vivo comparison of macrocyclic and acyclic ligands.
Hens M; Vaidyanathan G; Zhao XG; Bigner DD; Zalutsky MR
Nucl Med Biol; 2010 Oct; 37(7):741-50. PubMed ID: 20870149
[TBL] [Abstract][Full Text] [Related]
11. Effectiveness and normal tissue toxicity of Auger electron (AE) radioimmunotherapy (RIT) with [
Chan C; Fonge H; Lam K; Reilly RM
Nucl Med Biol; 2020; 80-81():37-44. PubMed ID: 31706737
[TBL] [Abstract][Full Text] [Related]
12. (90) Y/(177) Lu-labelled Cetuximab immunoconjugates: radiochemistry optimization to clinical dose formulation.
Chakravarty R; Chakraborty S; Sarma HD; Nair KV; Rajeswari A; Dash A
J Labelled Comp Radiopharm; 2016 Jul; 59(9):354-63. PubMed ID: 27264196
[TBL] [Abstract][Full Text] [Related]
13. Induction of different cellular arrest and molecular responses in low EGFR expressing A549 and high EGFR expressing A431 tumor cells treated with various doses of
Suman S; Priya R; Kameswaran M
Int J Radiat Biol; 2020 Sep; 96(9):1144-1156. PubMed ID: 32657634
[TBL] [Abstract][Full Text] [Related]
14. Leveraging a Dual Variable Domain Immunoglobulin to Create a Site-Specifically Modified Radioimmunoconjugate.
MacPherson DS; Hwang D; Sarrett SM; Keinänen O; Rodriguez C; Rader C; Zeglis BM
Mol Pharm; 2023 Jan; 20(1):775-782. PubMed ID: 36377696
[TBL] [Abstract][Full Text] [Related]
15. Preclinical Characterization of the
Striese F; Neuber C; Gräßel S; Arndt C; Ullrich M; Steinbach J; Pietzsch J; Bergmann R; Pietzsch HJ; Sihver W; Frenz M; Feldmann A; Bachmann MP
Int J Mol Sci; 2023 May; 24(11):. PubMed ID: 37298374
[TBL] [Abstract][Full Text] [Related]
16. Panitumumab Modified with Metal-Chelating Polymers (MCP) Complexed to
Aghevlian S; Lu Y; Winnik MA; Hedley DW; Reilly RM
Mol Pharm; 2018 Mar; 15(3):1150-1159. PubMed ID: 29314858
[TBL] [Abstract][Full Text] [Related]
17. Dual-Receptor-Targeted Radioimmunotherapy of Human Breast Cancer Xenografts in Athymic Mice Coexpressing HER2 and EGFR Using 177Lu- or 111In-Labeled Bispecific Radioimmunoconjugates.
Razumienko EJ; Chen JC; Cai Z; Chan C; Reilly RM
J Nucl Med; 2016 Mar; 57(3):444-52. PubMed ID: 26429962
[TBL] [Abstract][Full Text] [Related]
18. Labeling internalizing anti-epidermal growth factor receptor variant III monoclonal antibody with (177)Lu: in vitro comparison of acyclic and macrocyclic ligands.
Hens M; Vaidyanathan G; Welsh P; Zalutsky MR
Nucl Med Biol; 2009 Feb; 36(2):117-28. PubMed ID: 19217523
[TBL] [Abstract][Full Text] [Related]
19. Synthesis and application of a novel cysteine-based DTPA-NCS for targeted radioimmunotherapy.
Lee SY; Hong YD; Kim HS; Choi SJ
Nucl Med Biol; 2013 Apr; 40(3):424-9. PubMed ID: 23357082
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]